Dr. Reddy’s Laboratories Ltd announced on July 1 that it has launched Repatha (evolocumab) 140 mg/ml, the first and only PCSK9 Inhibitor available in India, approved by the Drug Controller General India (DCGI).

Repatha (evolocumab) is a patented product of Amgen global, indicated for the treatment of adult patients with primary  hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, Hyderabad-based major Pharmaceutical company said in a release on July 1.

It is used as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin. M.V. Ramana, CEO, Branded Markets (India and Emerging Markets) said, “The launch of Repatha™ is another significant addition to Dr. Reddy’s Cardiovascular portfolio, which we believe will provide a unique treatment option to patients in India who are at risk of Heart Attack, Stroke and Coronary problems.” In India, Repatha is distributed by Dr. Reddy’s and manufactured by Amgen.